KO 947
Alternative Names: KO-947Latest Information Update: 31 Oct 2021
At a glance
- Originator Araxes Pharma
- Developer Araxes Pharma; Kura Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 05 May 2020 Kura Oncology discontinues phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Spain and USA (IV) (NCT03051035)
- 05 May 2020 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (IV)
- 05 May 2020 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)